alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
[Federal Register Volume 60, Number 28 (Friday, February 10, 1995)]
[Notices]
[Page 7947]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-3312]



[[Page 7947]]

DEPARTMENT OF DEFENSE

Office of the Secretary


Joint Advisory Committee on Nuclear Weapons Surety; Meeting

ACTION: Notice of Advisory Committee Meeting.

-----------------------------------------------------------------------

SUMMARY: The Joint Advisory Committee (JAC) on Nuclear Weapons Surety 
will meet in closed session on March 16-17, 1995, at the Science 
Applications International Corporation (SAIC), San Diego, California.
    The Joint Advisory Committee is charged with advising the Secretary 
of Defense, Secretary of Energy, and the Joint Nuclear Weapons Council 
on nuclear weapons systems surety matters. At this meeting, the Joint 
Advisory Committee will receive classified briefings on the capability 
of the DoD to maintain nuclear readiness, the status of the Stockpile 
Stewardship program and conduct an independent review of the role of 
the Nevada Test Site (NTS) in supporting Defense programs.
    In accordance with the Federal Advisory Committee Act (Pub. L. 92-
463, as amended, Title 5, U.S.C. App. II, (1988)), this meeting 
concerns matters, sensitive to the interests of national security, 
listed in 5 U.S.C. section 552b (c)(1) and accordingly this meeting 
will be closed to the public.

    Dated: February 6, 1995.
Patricia L. Toppings,
Alternate OSD Federal Register Liaison Officer, Department of Defense.
[FR Doc. 95-3312 Filed 2-9-95; 8:45 am]
BILLING CODE 5000-04-M
FILED

U.S. COURT OF APPEALS

ELEVENTH CIRCUIT

JULY 07, 2010

JOHN LEY

 CLERK

[DO NOT PUBLISH]

IN THE UNITED STATES COURT OF APPEALS

FOR THE ELEVENTH CIRCUIT

________________________

No. 09-13117

Non-Argument Calendar

________________________

D. C. Docket No. 08-20567-CR-AJ

UNITED STATES OF AMERICA,

Plaintiff-Appellee,

versus

MARILYN DE LA PAZ,

a.k.a. Marilyn Martis,

Defendant-Appellant.

________________________

Appeal from the United States District Court

for the Southern District of Florida

_________________________

(July 7, 2010)

Before BLACK, PRYOR and HILL, Circuit Judges.

PER CURIAM:

Thomas John Butler, appointed counsel for Marilyn De La Paz in this direct
criminal appeal, has moved to withdraw from further representation of the

appellant and filed a brief pursuant to Anders v. California, 386 U.S. 738, 87 S.Ct.

1396, 18 L.Ed.2d 493 (1967). Our independent review of the entire record reveals

that counsel’s assessment of the relative merit of the appeal is correct. Because

independent examination of the entire record reveals no arguable issues of merit,

counsel’s motion to withdraw is GRANTED, and De La Paz’s convictions and

sentences are AFFIRMED.

2
| Skip to contentSocial Security Online | Actuarial Publications |
|---------------------------------------|------------------------|

| www.socialsecurity.gov | Home  FAQs  Contact Us  Search | **Search**  |
|------------------------|-----------------------------------------------------------------|------------------|

| Solvency provisions | Summary Measures and Graphs |
|---------------------|-----------------------------|

| Level of Monthly Benefits (PIA) | Description of Proposed Provision:      Progressive price indexing of PIA formula factors beginning with individuals newly eligible for OASI benefits in 2016. Create new bend point at the 30th percentile of earners. Maintain current-law benefits for earners at the 30th percentile and below and reduce upper 2 formula factors (32% and 15%) such that maximum worker benefit grows by inflation rather than the growth in average wages. Disability benefits are not affected by the proposal. Disabled worker beneficiaries, upon attaining normal retirement age, would be subject to a proportional reduction in benefits based on the worker's years of disability. |
|---------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                 |

*Estimates based on the intermediate assumptions        of the 2008 Trustees Report*

|  |  |
|--|--|

|        |
|--------|
|   | Privacy Policy      | Website Policies        & Other Important Information      | Site Map     Last reviewed or modified July 16, 2008 |
Exhibit 10.3


 


 


November 30, 2022


 


Holder of Warrants to Purchase Common Stock issued on December 28,
2020 and January 10, 2022


 


Re: Amendment to Existing Warrants


 


Dear Holder:


 


Reference is hereby made to the concurrent public offering on or about
the date hereof (the “Offering”) by CNS Pharmaceuticals, Inc. (the “Company”) of its securities (collectively,
the “Securities”).


 


This letter confirms that, in consideration for the Holder’s
participation in the Offering and purchase of Securities in the Offering (the “Purchase Commitment”), the Company hereby amends,
effective as of the closing of the Offering, the Holder’s existing warrants to purchase up to 16,667 shares of common stock at an
exercise price of $66.00 per share, as adjusted, issued on December 28, 2020 and existing warrants to purchase up to 210,527 shares of
common stock at an exercise price of $24.60 per share, as adjusted, issued on January 10, 2022 (collectively, the “Existing Warrants”),
by (i) reducing the Exercise Price (as defined therein) of the Existing Warrants to $3.03 per share, and (ii) amending the expiration
date of the Existing Warrants to five (5) years following the closing of the Offering (the “Warrant Amendment”). The Warrant
Amendment shall be effective upon the closing the Offering and the satisfaction of the other terms and conditions referenced below.


 


The Warrant Amendment is subject to the consummation of the Offering
and the Holder’s satisfaction of the Purchase Commitment. In the event that either (i) the Offering is not consummated, or (ii)
the Holder does not satisfy the Purchase Commitment, the Warrant Amendment shall be null and void and the provisions of the Existing Warrants
in effect prior to the date hereof shall remain in effect.


 


Except as expressly set forth herein, the terms and provisions of the
Existing Warrants shall remain in full force and effect after the execution of this letter and shall not be in any way changed, modified
or superseded except by the terms set forth herein.


 


From and after the effectiveness of the Warrant Amendment, the Company
agrees to promptly deliver to the Holder, upon request, amended Existing Warrants that reflect the Warrant Amendments in exchange for
the surrender for cancellation of the Holder’s Existing Warrants to be amended as provided herein.


 


 


 


[Signature Page Follows]


 


 


 


 


 


 


 


 


 






    	 	1	 



     


    

 


IN WITNESS WHEREOF, the parties hereto have caused
this agreement to be duly executed by their respective authorized signatories as of the date first indicated above.


 


CNS PHARMACEUTICALS, INC.


 


By: ____________________


Name:


Title:


 


 


Name of Holder: ______________________________________________________________


 


Signature of Authorized Signatory of Holder: ________________________________________


 


Name of Authorized Signatory: ___________________________________________________


 


 


 


 


 


 


 


 


 


 


 


 


 






    	 	2
### Proposed Provision: B1.5. Progressive price indexing (60th percentile) of PIA factors beginning with individuals newly eligible for OASDI benefits in 2030: Create a new bend point at the 60th percentile of the AIME distribution of newly retired workers. Maintain current-law benefits for earners at the 60th percentile and below. Reduce the 32 and 15 percent factors above the 60th percentile such that the initial benefit for a worker with AIME equal to the taxable maximum grows by inflation rather than the growth in the SSA average wage index.
#### IN THE MATTER OF H. C. SCALES, Respondent.

(Filed 9 November, 1932.)

Appeal by respondent from *Shaw, Emergency Judge,*at June Term, 1932, of Fobsyth.

Affirmed.

*Joe W. Johnson and S. E. Hall for respondent.*

*Attorney-General Brummitt and Assistant Attorney-General Seawell for the State.*

*852Per Curiam.

In the Forsyth County Court it was adjudged that the respondent be attached for contempt growing out of his disobedience of a restraining order. In the Superior Court the appeal was dismissed and the respondent was committed to the custody of the sheriff. The judgment is

Affirmed.
Long-range 

actuarial 

balance

Annual 

balance in 

75th year

Long-range 

actuarial 

balance

Annual 

balance in 

75th year

Long-range 

actuarial 

balance

Annual 

balance in 

75th year

-3.61 -4.35 0.19 0.14 5% 3%

Estimates based on the intermediate assumptions of the 2023 Trustees Report Office of the Chief Actuary

Social Security Administration

September 15, 2023

Summary Measures and Graphs

Category of Change: Payroll Taxes (including maximum taxable)

Current law

[percent of payroll]

Change from current law

[percent of payroll] Shortfall eliminated

Proposed Provision: E3.8. Beginning in 2031, apply 2 percent payroll tax rate on earnings over the wageindexed equivalent of $200,000 in 2017 (about $348,300 in 2031), with the threshold wage-indexed after 

2031. Provide proportional benefit credit for additional earnings taxed, based on the payroll tax rate applied 

to the additional earnings divided by the full 12.4 percent payroll tax rate.

6.0

8.0

10.0

12.0

14.0

16.0

18.0

20.0

2023 2030 2040 2050 2060 2070 2080 2090

Percent

Year

OASDI Cost Rates and Income Rates

(as a percentage of taxable payroll)

Income rates under current law

Income rates with this provision

Cost rates under current law

Cost rates with this provision

0

100

200

300

400

500

600

2023 2030 2040 2050 2060 2070 2080 2090

Percent

Year

OASDI Trust Fund Ratio

(assets as a percentage of annual expenditures)

Current law With this provision
Exhibit 32.1

SECTION 1350 CERTIFICATION OF CHIEF EXECUTIVE OFFICER

I, Friedhelm Blobel, Chief Executive
Officer of SciClone Pharmaceuticals, Inc. (the Registrant), do hereby certify in accordance with 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, based on my knowledge:



|(1) | the Amendment to Annual Report on Form 10-K/A of the Registrant, to which this certification is attached as an exhibit (the Report), fully complies with the
requirements of section 13(a) of the Securities Exchange Act of 1934 (15 U.S.C. 78m); and
|--- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|(2) | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.
|--- | -------------------------------------------------------------------------------------------------------------------------------------------------------



|                     |  |  |  |  |  |                                                
|-------------------- |  |  |  |  |  | -----------------------------------------------
|                     |  |  |  |  |  | /s/ Friedhelm Blobel                           
|Date: April 30, 2013 |  |  |  |  |  | Friedhelm Blobel, Ph.D. Chief Executive Officer
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED
FROM THE CONSOLIDATED BALANCE SHEETS AND CONSOLIDATED STATEMENTS
OF OPERATIONS CONTAINED IN THE COMPANY'S ANNUAL REPORT ON FORM
10-K FOR THE YEAR ENDED DECEMBER 31, 1996 AND IS QUALIFIED IN ITS
ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
       
<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                  DEC-31-1997
<PERIOD-START>                     JAN-01-1997
<PERIOD-END>                       DEC-31-1997
<CASH>                               1,202,668
<SECURITIES>                         7,253,756
<RECEIVABLES>                          431,046
<ALLOWANCES>                                 0
<INVENTORY>                            826,008
<CURRENT-ASSETS>                     9,931,991
<PP&E>                               4,707,848
<DEPRECIATION>                       2,989,698
<TOTAL-ASSETS>                      15,753,903
<CURRENT-LIABILITIES>                5,369,071
<BONDS>                              2,204,053
<PREFERRED-MANDATORY>                        0
<PREFERRED>                                684
<COMMON>                                 5,712
<OTHER-SE>                           9,418,602
<TOTAL-LIABILITY-AND-EQUITY>        15,753,903
<SALES>                              4,701,649
<TOTAL-REVENUES>                     5,101,746
<CGS>                                3,099,078
<TOTAL-COSTS>                       16,561,402
<OTHER-EXPENSES>                             0
<LOSS-PROVISION>                             0
<INTEREST-EXPENSE>                     227,160
<INCOME-PRETAX>                              0
<INCOME-TAX>                                 0
<INCOME-CONTINUING>                          0
<DISCONTINUED>                               0
<EXTRAORDINARY>                              0
<CHANGES>                                    0
<NET-INCOME>                       (12,425,817)
<EPS-PRIMARY>                            (6.85)
<EPS-DILUTED>                                0
        


</TABLE>
Exhibit 23.2

                         INDEPENDENT AUDITORS' CONSENT

      We consent to the incorporation by reference in this Registration
Statement Nos. 33-72130, 33-58362, 333-3846, 333-35215, 333-40634, 333-50330 and
333-75134 of Genta Incorporated on Form S-3 and Registration Statement Nos.
33-85887, 333-94181, 333-101022 of Genta Incorporated on Form S-8 or our report
dated February 13, 2003 (except Note 21, as to which the date is March 17, 2003)
with respect to the consolidated financial statements of Genta Incorporated and
subsidiaries, appearing in the Annual Report on Form 10-K for the year ended
December 31, 2002.


/s/ DELOITTE & TOUCHE LLP

Parsippany, New Jersey
March 31, 2003
**Exhibit 31.2**
**CERTIFICATION**
I, Greg Petersen, certify that:
1. I have reviewed this quarterly report on Form 10-Q of ActivantSolutions Inc.; 2. Based on my knowledge, this report does not contain any untruestatement of a material fact or omit to state a material fact necessaryto make the statements made, in light of the circumstances under whichsuch statements were made, not misleading with respect to the periodcovered by this report; 3. Based on my knowledge, the financial statements, and otherfinancial information included in this report, fairly present in allmaterial respects the financial condition, results of operations andcash flows of the registrant as of, and for, the periods presented inthis report; 4. The registrant’s other certifying officer(s) and I are responsiblefor establishing and maintaining disclosure controls and procedures (asdefined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for theregistrant and have:
(a) Designed such disclosure controls and procedures, orcaused such disclosure controls and procedures to be designedunder our supervision, to ensure that material informationrelating to the registrant, including its consolidatedsubsidiaries, is made known to us by others within thoseentities, particularly during the period in which this report isbeing prepared; (b) Evaluated the effectiveness of the registrant’sdisclosure controls and procedures and presented in this reportour conclusions about the effectiveness of the disclosurecontrols and procedures, as of the end of the period covered bythis report based on such evaluation; and (c) Disclosed in this report any change in theregistrant’s internal control over financial reporting thatoccurred during the registrant’s most recent fiscal quarter (theregistrant’s fourth fiscal quarter in the case of an annualreport) that has materially affected, or is reasonably likely tomaterially affect, the registrant’s internal control overfinancial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed,based on our most recent evaluation of internal control over financialreporting, to the registrant’s auditors and the audit committee of theregistrant’s board of directors (or persons performing the equivalentfunctions):
(a) All significant deficiencies and material weaknessesin the design or operation of internal control over financialreporting which are reasonably likely to adversely affect theregistrant’s ability to record, process, summarize and reportfinancial information; and (b) Any fraud, whether or not material, that involvesmanagement or other employees who have a significant role in theregistrant’s internal control over financial reporting.
Date: August 13, 2004    /s/ GREG PETERSEN  Greg Petersen Senior Vice President and Chief Financial Officer
Exhibit 32.1

     CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
                            (18 U.S.C. SECTION 1350)

      In connection with the accompanying Annual Report of Genta Incorporated
(the "Company") on Form 10-K for the year ended December 31, 2003 (the
"Report"), I, Raymond P.Warrell, Chief Executive Officer of the Company,
certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906
of the Sarbanes-Oxley Act of 2002, that:

      (1)   The Report fully complies with the requirements of Section 13(a) of
            the Securities Exchange Act of 1934; and

      (2)   The information contained in the Report fairly presents, in all
            material respects, the financial condition and results of operations
            of the Company.

Date: March 12, 2004
      --------------


/s/ RAYMOND P. WARRELL, JR., M.D.
---------------------------------
Name:  Raymond P. Warrell, Jr., M.D.
Title: Chief Executive Officer


                                       79
II 

117TH CONGRESS 

2D SESSION S. 3548 

To amend title 38, United States Code, to establish a presumption of serviceconnection for certain veterans with tinnitus or hearing loss, and for 

other purposes. 

IN THE SENATE OF THE UNITED STATES 

FEBRUARY 1, 2022 

Ms. SMITH (for herself and Mr. SANDERS) introduced the following bill; which 

was read twice and referred to the Committee on Veterans’ Affairs 

A BILL 

To amend title 38, United States Code, to establish a presumption of service-connection for certain veterans with 

tinnitus or hearing loss, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Veterans Hearing Ben5 efits Act of 2022’’. 


kjohnson on DSK79L0C42PROD with BILLS
2 

•S 3548 IS

1 SEC. 2. PRESUMPTION OF SERVICE-CONNECTION FOR 

2 HEARING LOSS AND TINNITUS. 

3 Section 1112 of title 38, United States Code, is 

4 amended by adding at the end the following new sub5 section: 

6 ‘‘(d)(1) For purposes of section 1110 of this title, and 

7 subject to the provisions of section 1113 of this title, diag8 nosed hearing loss, tinnitus, or both of a veteran described 

9 in paragraph (2) shall be considered to have been incurred 

10 in or aggravated by the active military, naval, or air serv11 ice of the veteran, notwithstanding that there is no record 

12 of evidence of such hearing loss or tinnitus, as the case 

13 may be, during the period of such service. 

14 ‘‘(2) A veteran described in this paragraph is a vet15 eran who while on active military, naval, or air service— 

16 ‘‘(A) was assigned to a military occupational 

17 specialty or equivalent described in paragraph (3); 

18 or 

19 ‘‘(B) served in combat. 

20 ‘‘(3) A military occupational specialty or equivalent 

21 referred to in paragraph (2)(A) is a military occupational 

22 specialty or equivalent in which individuals assigned to 

23 such military occupational specialty or equivalent in the 

24 active military, naval, or air service are or were likely to 

25 be exposed to a sufficiently high level of acoustic trauma 


kjohnson on DSK79L0C42PROD with BILLS
3 

•S 3548 IS

1 as to result in permanent hearing loss, tinnitus, or both, 

2 as determined by the Secretary.’’. 

3 SEC. 3. MODIFICATION TO SCHEDULE FOR RATES FOR DIS4 ABILITY COMPENSATION. 

5 Pursuant to section 1155 of title 38, United States 

6 Code, the Secretary of Veterans Affairs shall adjust the 

7 schedule of rating disabilities to establish a minimum dis8 ability rating for a veteran who requires a hearing aid be9 cause of a service-connected disability, including pursuant 

10 to section 1112(d) of such title, as amended by section 

11 2. 

Æ 


kjohnson on DSK79L0C42PROD with BILLS
<PAGE>

                                                          EXHIBIT  10.78

                    Amendment No. 1 to Employment Agreement

     This Amendment No. 1 to Employment Agreement is entered into as of this 3rd
day of December 1999, by and between Vertel Corporation, a California
corporation (the "Company") and Gordon L. Almquist, an individual ("Officer"),
with respect to the following facts:

        A.  On January 12, 1999, the Company and Officer entered into a written
            Employment Agreement (the "Employment Agreement").

        B.  On December 3, 1999, the Company's Compensation Committee approved
            an amendment to Officer's Employment Agreement as hereinafter set
            forth.

     Now, therefore, in consideration of the foregoing and intending to be
mutually bound, the parties hereto agree as follows:

        1.  Section 5(b)(ii)(A) of the Employment Agreement shall be amended
          to read as follows:

          "Salary Continuance.  If Officer experiences an Involuntary
           ------------------
          Termination before the second year anniversary of the date of this
          Agreement, Officer will be entitled to receive an amount equal to his
          or her regular monthly salary (subject to any applicable tax
          withholding) as of the time of termination for twelve (12) months
          following such termination (the "Original Term Severance Period").  If
                                           ------------------------------
          Officer experiences an Involuntary Termination during any period of
          the Agreement following the second year anniversary of the date of
          this Agreement . . . ."

The remainder of such paragraph shall remain as currently written in the
Employment Agreement.

        2.  All other terms and conditions of the Agreement not expressly
amended herein shall remain in full force and effect without any change

                            [Signature Page Follows]
<PAGE>

    The parties have executed this Agreement the date first written above.

                         VERTEL CORPORATION


                         By:_____________________________________________
                         Bruce W. Brown, President and Chief Executive Officer

                         Address:       21300 Victory Blvd., #1200
                                        Woodland Hills, CA 91367



                         NAME:          Gordon L. Almquist

                         Signature:  __________________________________


                         Address:
                                        -------------------------------
                                        -------------------------------